Table 1 Association between ZEB1 expression and clinicopathological factors in breast cancer
Variables | Number (%) | Number (%) | p value |
|---|---|---|---|
ZEB1 negative and weak expression | ZEB1 strong expression | ||
Age | |||
 > 50 | 23 (30.6) | 14 (18.7) | 0.015 |
 ≤ 50 | 13 (17.3) | 25 (33.3) | |
Tumor size (cm) | |||
 > 5 | 19 (16.8) | 23 (30.7) | 0.308 |
 ≤ 5 | 17 (22.7) | 16 (21.3) | |
ER status | |||
 Positive | 25 (33.3) | 32 (42.7) | 0.202 |
 Negative | 11 (14.7) | 7 (9.3) | |
PR status | |||
 Positive | 32 (42.7) | 32 (42.7) | 0.403 |
 Negative | 4 (5.3) | 7 (9.3) | |
Ki-67 status (%) | |||
 > 30 | 17 (23.7) | 22 (29.3) | 0.426 |
 ≤ 30 | 19 (25.3) | 17 (23.7) | |
HER2 | |||
 Positive | 13 (17.3) | 15 (20.0) | 0.833 |
 Negative | 23 (30.6) | 24 (32.0) | |
Lymph node positive | |||
 > 0 | 15 (20.0) | 23 (30.6) | 0.134 |
 ≤ 0 | 21 (28.0) | 16 (21.3) | |
Menopausal status | |||
 Premenopausal | 23 (30.6) | 14 (18.7) | 0.015 |
 Postmenopausal | 13 (17.3) | 25 (33.3) | |